Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Tsuda

Showing results (71-80 of 476) with videos related to

Pageof 48
Sort By:
The American Journal of Surgical Pathology|August 11, 2010
Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variantAkihiko Yoshida, Tetsuo Ushiku, Toru Motoi, et al.
Histopathology|June 16, 2010
Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinomaSohei Yamamoto, Hitoshi Tsuda, Kosuke Miyai, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 12, 2011
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patientSohei Yamamoto, Hitoshi Tsuda, Kosuke Miyai, et al.
Acta Neurochirurgica|October 30, 2008
Pilomyxoid astrocytoma of the fourth ventricle in an adultTomoko Omura, Hiroshi Nawashiro, Hideo Osada, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 11, 2011
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomasSohei Yamamoto, Hitoshi Tsuda, Kosuke Miyai, et al.
Journal of Proteomics|August 6, 2013
Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcomaDaisuke Kubota, Kenta Mukaihara, Akihiko Yoshida, et al.
Clinical Breast Cancer|October 30, 2012
Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapySota Asaga, Takayuki Kinoshita, Takashi Hojo, et al.
Photodiagnosis and Photodynamic Therapy|October 25, 2023
Transvascular delivery of talaporfin sodium to subcutaneous tumors in mice by nanosecond pulsed laser-induced photomechanical wavesYasuyuki Tsunoi, Satoko Kawauchi, Naoki Yamada, et al.
Cancer Science|May 8, 2021
Identification of PDHX as a metabolic target for esophageal squamous cell carcinomaJun Inoue, Masahiro Kishikawa, Hitoshi Tsuda, et al.
The Journal of Pathology|July 8, 2011
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinomaSohei Yamamoto, Hitoshi Tsuda, Masashi Takano, et al.
Pageof 48

Showing results (71-80 of 476) with videos related to

Sort By:
Pageof 48
The American Journal of Surgical Pathology|August 11, 2010
Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variantAkihiko Yoshida, Tetsuo Ushiku, Toru Motoi, et al.
Histopathology|June 16, 2010
Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinomaSohei Yamamoto, Hitoshi Tsuda, Kosuke Miyai, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 12, 2011
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patientSohei Yamamoto, Hitoshi Tsuda, Kosuke Miyai, et al.
Acta Neurochirurgica|October 30, 2008
Pilomyxoid astrocytoma of the fourth ventricle in an adultTomoko Omura, Hiroshi Nawashiro, Hideo Osada, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 11, 2011
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomasSohei Yamamoto, Hitoshi Tsuda, Kosuke Miyai, et al.
Journal of Proteomics|August 6, 2013
Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcomaDaisuke Kubota, Kenta Mukaihara, Akihiko Yoshida, et al.
Clinical Breast Cancer|October 30, 2012
Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapySota Asaga, Takayuki Kinoshita, Takashi Hojo, et al.
Photodiagnosis and Photodynamic Therapy|October 25, 2023
Transvascular delivery of talaporfin sodium to subcutaneous tumors in mice by nanosecond pulsed laser-induced photomechanical wavesYasuyuki Tsunoi, Satoko Kawauchi, Naoki Yamada, et al.
Cancer Science|May 8, 2021
Identification of PDHX as a metabolic target for esophageal squamous cell carcinomaJun Inoue, Masahiro Kishikawa, Hitoshi Tsuda, et al.
The Journal of Pathology|July 8, 2011
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinomaSohei Yamamoto, Hitoshi Tsuda, Masashi Takano, et al.
Pageof 48